2024-12-29 14:00:32
Vivek’s company, Roivant Sciences, was acquired for billions. This does not mean Vivek himself made billions. Roivant had 800 employees at the time it was acquired in 2021 [Link][Link] NEEDS_MORE_RATINGS(49-2-15) Author
2024-12-30 00:26:10
Vivek Ramaswamy reported $175MM in capital gains from the sale of the relevant investor behind Axovant (Roivant). While still considerable, and the crux of the point may still have merit, "billions" is an inaccurate number. [Link] NEEDS_MORE_RATINGS(3-1-3) Author
2024-12-30 01:11:01
Vivek, founder of Roivant (NASDAQ: ROIV), led a firm that developed FDA-approved drugs. Axovant, a Roivant subsidiary, worked on an Alzheimer’s drug that failed—a fate shared by 99% of such drugs. Neither Vivek nor Roivant sold Axovant shares before its failure. [Link] NEEDS_MORE_RATINGS(9-0-8) Author
2024-12-30 01:55:38
Vivek developed a drug for Alzheimer’s through a subsidiary of Roivant, Axovant. This drug failed, like most Alzheimer’s drugs. Vivek did not profit from it, choosing not to sell shares in Axovant before its collapse. Roivant also avoided such sales. Blatant lies in post. [Link] NEEDS_MORE_RATINGS(19-0-9) Author
2024-12-30 11:35:03
There is no proof for this claim and no link to check the accusations [Link] NEEDS_MORE_RATINGS(1-0-4) Author